GSK profit beats on Shingrix, demand for pain meds during pandemic [Yahoo! Finance News]
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Yahoo! Finance News
FILE PHOTO: A GSK logo is seen at the GSK research centre in Stevenage) - GlaxoSmithKline's first-quarter profit beat analysts' expectations on Wednesday due to strong demand for its blockbuster shingles vaccine and higher sales of some of its pain relief medicines during the coronavirus pandemic.Like its rival AstraZeneca , the British drugmaker stuck to its 2020 forecast and still expects a 1% to 4% fall in profit for the year.Turnover rose 19% to 9.09 billion pounds $11.26 billion) in the three months ended March 31 from a year earlier, while adjusted earnings were 37.7 pence per share.Shingrix sales came in at 647 million pounds, beating consensus estimate by 23%, while consumer health business brought in 2.86 billion pounds, ahead of estimates of 2.78 billion pounds.Analysts on average expected first-quarter adjusted earnings of 31.5 pence per share and sales of 8.75 billion pounds, according to a company-compiled consensus of 13 analysts.In the race to develop a vaccine to end
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GSK (NYSE:GSK) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Deutsche Bank Maintains a Hold Rating on GSK plc (GSK) [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
GSK
Sec Filings
- 12/5/25 - Form 6-K
- 12/4/25 - Form 6-K
- 12/3/25 - Form 6-K
- GSK's page on the SEC website